Labcorp Holdings Inc. LH
Healthcare · Diagnostics & Research · United States · S&P 500
Based on the available data, Labcorp Holdings Inc. gets an algorithmic score of 66/100. It trades at 308.81 $, with a bullish technical trend (RSI 41.4) and 24.0% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low beta (0.51): defensive profile.
- Meaningful dividend (93.00%).
Weaknesses
- —
Fundamentals
| P/E | 25.52 |
| Forward P/E | 15.57 |
| PEG | 1.21 |
| P/B | 2.90 |
| EV/EBITDA | 13.68 |
| P/S | 1.75 |
| ROE % | 11.73 |
| ROA % | 5.53 |
| Gross margin % | 28.88 |
| Operating margin % | 12.24 |
| Net margin % | 6.99 |
| Revenue growth % (y/y) | 5.80 |
| Earnings growth % (y/y) | 28.20 |
| Revenue CAGR % | 5.55 |
| Earnings CAGR % | -11.84 |
| Debt/Equity % | 79.12 |
| Current ratio | 1.80 |
| FCF yield % | 4.82 |
| Dividend yield % | 93.00 |
| Payout % | 23.82 |
Returns
| 1 month | -7.8 % |
| 3 months | +10.5 % |
| 6 months | +17.7 % |
| YTD | +23.6 % |
| 1 year | +11.2 % |
| 3 years | +55.9 % |
| 5 years | +28.9 % |
Risk
| 1-year volatility | 24.0 % |
| Beta | 0.51 |
| 5-year max drawdown | -34.6 % |
| Sharpe 1A | 0.39 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.